• The Spanish Biotechnological increases 152% its Net Income.
  • Group’s Earning before Interest and Taxes raised in 2014 386%, to reach €756.000, compared with the €156.000 registered in the past year.
  • Bionaturis Group reported revenue in full year 2014 soars to €3.03 million, an increase of 73% compared with last year.

Bionaturis Group, Spanish biopharmaceutical Group (ticker BNT) focusing its activity on the development of biological medicines for human and animal health, has reached in year 2014 €931.000 of EBITDA in full year 2014 results, increased of 29% compared with last year. Bionaturis Group Net Income was €1.19 million in 2014, a growth of 152 % compared to the same period of the previous year.

Furthermore, the total amount of income was €3.03 million, which means an increase of 73% compared to the last year. This increase is basically due to the rise of net sales in 116% compared to 2013.

2014 has been the first year consolidating the figures of BBD Biophenix, company specialized in advanced systems of drug discovery  acquired last May, 2014. A strategic acquisition for Bionaturis to support its growth and international expansion, at the time that contributes to its vision of facilitating industry the drug development process. With this transaction, Bionaturis extends its international presence and multinational customers portfolio, such as, Sanofi, Roche, Servier and Royal Dutch Shell Group, among others.

Performance evolution for business areas

The evolution of Bionaturis Group’s business divisions have been aligned with the foreseen. In this regard, the human and animal health area has extended throughout 2014 the collaborative developments with third parties (BNTs) and has reached important milestones as the beginning of collaboration programs in human health with two US-based biotech Companies.

Meanwhile, the CRO division (Contract Research Organization), included BBD Biophenix, has significantly extended its added-value services range as well as its multinational clients portfolio.

Finally, the results deviation in the division of consumer products, BNT Dermocosmetics, due to the significant increase in sector competition and the consumption drop, already communicated to the MAB, we expect to be compensated by joining Osei Pharma last October, strengthening the commercial network and, therefore, the sales.

In the same way, we highlight that new M&As are being considered in order to fuel the Bionaturis Group inorganic growth throughout the acquisition of a Contract Manufacturing Organization, which will allow the Group to grow in the value chain, broadening significantly its capacity of services.

According to Bionaturis Group CEO, Victor Manuel Infante, “these results show our ability to progress and to provide added-value to our shareholders and the whole Society as well”.

International expansion

At international level there is a strong commitment of Bionaturis Group, making an outstanding effort in prospecting and sales activity, working along entities of great experience and recognition both in the Chinese and LATAM market. The aim is to gain size and diversification to strengthen the Group structure and to be able to compete with guarantees in international markets.

The performance of the Group has also crossed Spain boundaries. Last November in Brussels, Bionaturis was honored with the highest prize in the well-regarded Small and Mid-Cap Awards, at Rising Star category, awards organized by the European Commission’s Directorate-General for Enterprise and Industry (DG ENTR) in collaboration with EuropeanIssuers and FESE (Federation of European Securities Exchanges)

About Bionaturis

Bionaturis Group is a Spanish biopharmaceutical Group, listing in Madrid on the Alternative Stock Exchange Market (MAB) since 2012, focusing its activity on the research, development and manufacturing of cutting-edge biotechnological solutions in order to improve a global access to health for persons and animals. Bionaturis Group is headquartered  in Jerez (Spain) and has research, development and manufacturing facilities in Jerez –FLYLIFE- and San Sebastian (Spain)  -BBD BIOPHENIX-. Nowadays it is in the springboard of its international expansion in Asia and Latam.


For the official disclosing about the financial results, please click here


For further information:

Virginia Montero: press@bionaturis.com

Phone: (+34) 856 818 424

(+34) 655 311047